Trials / Completed
CompletedNCT05550597
Comparison of the Time to the First Rescue Analgesic Among Parturients Receiving Intrathecal Additive Fentanyl or Intrathecal Fentanyl With TAP Block or TAP Block Alone for Elective Cesarean Sections Under Hyperbaric Bupivacaine Spinal Anesthesia
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 93 (actual)
- Sponsor
- Nepal Mediciti Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
The postoperative pain management after cesarean section under spinal anestheisa is done using various modalities. The commonly used regimens are systemic NSAIDs/Opioids, USG guided TAP block or Intrathecal additive Fentanyl or combined intrathecal fentanyl and USG guided TAP block. Investigators aim to compare the postoperative analgesia in terms of time to the first rescue analgesic in parturients receiving intrathecal additive fentanyl only, or intrathecal fentanyl with USG guided TAP block or USG guided TAP block alone for elective CS done under hyperbaric bupivacaine spinal anesthesia.
Detailed description
Investigators will enroll 93 parturients planned for elective CS under hyperbaric bupivacaine spinal anesthesia and allocate them into three groups comprising intrathecal additive fentanyl only, or intrathecal fentanyl with USG guided TAP block or USG guided TAP block alone. The primary outcome will be time to the first rescue analgesics.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fentanyl HCl | Intrathecal additive Fentanyl with Hyperbaric Bupivacaine during Spinal Anesthesia |
| DRUG | Bupivacaine 0.25% Injectable Solution | Intrathecal additive Fentanyl with Hyperbaric Bupivacaine during Spinal Anesthesia Ultrasound-guided Transversus Abdominal plane block using Bupivacaine 0.25% Injectable Solution |
Timeline
- Start date
- 2022-08-15
- Primary completion
- 2023-02-20
- Completion
- 2023-03-15
- First posted
- 2022-09-22
- Last updated
- 2023-03-27
Locations
1 site across 1 country: Nepal
Source: ClinicalTrials.gov record NCT05550597. Inclusion in this directory is not an endorsement.